Dinutuximab beta‑targeted therapy kills beta‑cell tumors of the pancreas

Purpose Dinutuximab beta is a monoclonal antibody used only in glioblastoma.Streptozotocin is an agent that is particularly toxic to pancreatic beta cells.Dinutuximab beta causes cytotoxicity through natural killer cells and neutrophils and shows effects.In this study,cytotoxicity was induced by streptozotocin without natural killer cells and neutrophils.Gaining the ability to show the effect of Dinutuximab beta without a natural killer was the first aim of this study.This will be especially important in cases where the immune system is deficient,such as cancer.The second aim of the study was to investigate the effects of Dinutuximab beta on cell viability and cell death in insulinoma under the conditions created.Methods The effect of Dinutuximab beta in the presence of natural killer cells in vivo was created by the application of Streptozotocin to Beta-cell tumors of the pancreas in vitro.The cell viability was determined with WST-1 assay.Reactive oxygen species were measured by using dichlorofluorescein diacetate as a spectrophotometer.The cells were marked with DAPI to indicate apoptotic markers(nuclear condensation and fragmentation)with the confocal microscope.GLUT2(Glucose transporter 2),IR(Insulin receptor),INS1,and INS2 expression levels were analyzed with q-RT-PCR.Results The cell cytotoxicity was induced by Streptozotocin.The cells proliferated with the administration of Dinutuximab beta alone.The result of Dinutuximab beta administered following Streptozotocin administration resulted in more cell death,increased ROS levels,GLUT2,Ins1,and Ins2 mRNA expression levels,and decreased IR mRNA expression levels.Furthermore,the cells predominantly died via apoptosis showing cytoplasmic condensation and DNA fragmentation.Conclusions The lethal effect of Dinutuximab beta without a natural killer was provided by Streptozotocin in Beta cell tumors of the pancreas.

临床药师对1例高危神经母细胞瘤患儿使用达妥昔单抗β的药学监护

本研究报道临床药师对1例高危神经母细胞瘤患儿使用达妥昔单抗β进行药学监护,探讨临床药师在新的靶向药物治疗中发挥的作用。患儿在使用达妥昔单抗β过程中先后出现了疼痛、反复高热(热峰40℃)、毛细血管渗漏综合征(眼睑浮肿、血压降低)、腹泻、低血钾(2.74 mmol·L^(-1))、呕吐等不良反应,临床医师给予止痛、退热、抗感染、利尿、止泻、补钾、止吐等对症治疗,临床药师对达妥昔单抗β、止痛药(吗啡、加巴喷丁)、抗菌药(头孢哌酮舒巴坦、伏立康唑)、止吐药(帕洛诺司琼)等药物的用法用量及剂量调整提出建议并被临床采纳,提高了患儿用药的有效性和安全性。

8例达妥昔单抗β所致不良反应的回顾性分析

目的:分析达妥昔单抗β所致不良反应(adverse drug reaction,ADR)的发生情况及临床特点,为临床合理用药提供参考。方法:对我院2021年以来应用达妥昔单抗β发生不良反应的8例住院患者病例资料进行回顾性分析。结果:8例发生达妥昔单抗β相关不良反应中,临床主要表现为疼痛、发热、毛细血管渗漏综合征、腹泻、轻度过敏反应、肝病和血液学毒性,其中以发热最为常见。ADRs发生时间集中在3.5~7 d。结论:在临床合理使用达妥昔单抗β时,应提高临床工作者对达妥昔单抗β不良反应的监测,保障患者安全有效使用药物。